Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cu...
Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...
RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sector Perform and lowers the price targe...
Wells Fargo analyst Yanan Zhu maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-Weight and lowers the price target ...
Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target from ...
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target ...
Citizens analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the price...
JP Morgan analyst Brian Cheng downgrades Intellia Therapeutics (NASDAQ:NTLA) from Neutral to Underweight and lowers the pric...
